A double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability, pharmacokinetics, and activity of ISIS 113715 in patients with type 2 diabetes mellitus who have not received prior therapy

Trial Profile

A double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability, pharmacokinetics, and activity of ISIS 113715 in patients with type 2 diabetes mellitus who have not received prior therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs ISIS 113715 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Ionis Pharmaceuticals; Isis Pharmaceuticals
  • Most Recent Events

    • 16 Oct 2007 Status change from in progress to completed.
    • 30 Oct 2006 Status change
    • 21 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top